Biacore aims to speed up screening

Published: 27-Sep-2001


Biacore International, the Swedish-based company specialising in surface plasmon resonance (SPR)-based technology, has launched its analytical Biacore S51 system, designed to reduce critical bottlenecks in drug discovery at stages downstream of high-throughput screening (HTS).

The system claims to look at preclinical applications and provide more biological information on compound activity in a single assay than other technologies. One of the crucial rate-limiting steps of developing drugs faster and more efficiently is the conversion of HTS "hits" into lead compounds for preclinical evaluation. The Biacore S51 is designed to rapidly address key steps in the "hit"-to-lead selection process by combining Biacore's SPR technology with advanced instrumentation and software for higher throughput, enhanced data quality and reduced sample usage.

The Biacore S51 has been developed in collaboration with companies including GlaxoSmithKline, Millennium Pharmaceuticals and Pharmacia.

You may also like